Evaluating the L-MIND and RE-MIND2 Trials in the Real-World Setting

Opinion
Video

Matthew Lunning, DO, FACP, evaluates the clinical trial data from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on real-world outcomes.

Related Videos
Yi-Bin Chen, MD, an expert on GVHD
Yi-Bin Chen, MD, an expert on GVHD
Video 6 - "Quality of Life + Clinical Monitoring Outside the Transplant Center"
Video 5 - "Second-Line Medications and Toxicities in GVHD"
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Related Content
Positive Topline Data With Nana-val in EBV+ PTCL

Positive Topline Data With Nana-val in EBV+ PTCL

April 16th 2024
Article

Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

IND Application Submitted to FDA for SynKIR-310 Trial in R/R B-NHL

IND Application Submitted to FDA for SynKIR-310 Trial in R/R B-NHL

April 3rd 2024
Article

An investigational new drug application for SynKIR-310's phase 1 trial targeting relapsed/refractory B-cell non-Hodgkin lymphomas was submitted to the FDA.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment

PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment

March 27th 2024
Article

The first arm of the phase 2 PROSPECT study evaluating tirabrutinib for the treatment of relapsed/refractory primary central nervous system lymphoma has finished enrolling patients.

Read More

FDA Denies Approval of Odronextamab in DLBCL and Follicular Lymphoma

FDA Denies Approval of Odronextamab in DLBCL and Follicular Lymphoma

March 25th 2024
Article

The FDA issued a pair of complete response letters for the biologics license application for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Read More